MetaVia Employee Directory

Biotechnology ResearchMassachusetts, United States11-50 Employees

MetaVia is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for cardiometabolic diseases. Its lead programs include DA-1726 for obesity, a dual-receptor agonist designed for once-weekly administration that engages GLP-1 and glucagon pathways. In early clinical data, a Phase 1 multiple ascending dose study in obesity showed favorable trends in weight reduction, glucose control, and waist measurements. 

The company is also developing vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis, a GPR119 agonist that stimulates the release of gut hormones involved in metabolism. Preclinical studies indicated improvements in liver inflammation, lipid metabolism, weight, and glucose control, with Phase 2a data suggesting direct hepatic effects alongside glucose lowering. MetaVia benefits from a strategic partnership with Dong-A ST Co. Ltd., which provides access to research and development capabilities and CMC expertise to support its programs.

Sign up for free to view info

Company overview Email format